Saltigo set sights on supplying APIs to Japan
Saltigo, the German-based subsidiary of the LANXESS specialty chemicals group, is working towards becoming one of the leading western supplier for active pharmaceutical ingredients (APIs) in Japan.
Saltigo, the German-based subsidiary of the LANXESS specialty chemicals group, is working towards becoming one of the leading western supplier for active pharmaceutical ingredients (APIs) in Japan.
The company is set to showcase its services and products at CPhI Japan in Tokyo (9-11 April).
The Japanese pharmaceutical market with an estimated size of $73bn is the second largest market worldwide following the US. The recent amendment of the Japanese pharmaceutical affairs law in 2005 opened up ways for pharma companies to outsource the manufacturing of APIs to third parties.
In addition, Japanese pharma companies reorganised their businesses, pursuing larger funds for investments and broadening their sales networks to develop competitive new global blockbuster products. These changes offer Saltigo attractive opportunities to expand its business in Japan.
In the last five years, over 70% of clinical trials and new drug applications (NDAs) for new Japanese drugs initially took place in Europe and the US. Many Japanese pharma companies are also growing in overseas markets. With an established track record on good manufacturing practice (GMP) for FDA and EU regulatory, Saltigo offers tailored services to match the need of Japanese pharmaceutical companies seeking know-how and support in western regulatory. As one of the few western API suppliers with technical customer service representatives located in Japan, Saltigo can offer close communications to their customers in Japan, which is of especially high importance in the developing stage.
Saltigo has established its specialised customer service operations for the pharma industry in Tokyo in 2007 under the roof of LANXESS K.K.
